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Abstract
Background: Recreational drug use is a major cause of disease, injury, physical and mental impairment and death
in developed countries such as the United Kingdom and the United States. Alcohol, tobacco, cannabis, 3,4-
methylenedioxymethamphetamine (MDMA) and psilocybe mushrooms are recreational drugs with capacity to
cause harm. Cannabis, MDMA and psilocybin have reported therapeutic applications.
Objectives: The primary purpose of this study was to determine which of the three types of vendor (pharmacy,
shop and the black market) are perceived to be the most suitable for selling the substances discussed according to a
general population sample.
Methods: A sample of 105 UK nationals was selected for the survey. Participants were presented information
regarding reported relative dangers of alcohol, tobacco, cannabis, MDMA and psilocybin and potential thera-
peutic applications. Participants were then asked to review harm reduction strategies.
Results: It was found that participants concluded that pharmacists with available NHS support from GPs and
mental health workers are the most suitable vendors of cannabis, MDMA and psilocybin as opposed to regulated
shops or the black market (p< 0.001). There was a high level of support for selling cannabis in pharmacies both
for therapeutic use and for harm reduction purposes with a mean score of 7.0 out of 10. Participants (60) with a
university education were found to be more in favour of the substances being sold primarily in pharmacies (alcohol
5.6, tobacco 6.7, cannabis 7.6, MDMA 6.5 and psilocybin 6.5) than participants (45) with no university qualiﬁ-
cation (alcohol 5.0, tobacco 4.8, cannabis 6.3, MDMA 5.0 and psilocybin 5.1).
Conclusions: The data suggest that the university-educated participants are supportive of treating recreational
drug use as a health issue with GPs, mental health workers and pharmacists taking on roles.
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Introduction
Recreational drug use is one of the leading causes of
disease and premature death in the United Kingdom
with alcohol and tobacco being the primary causative
agents (ASH, 2015; Connor, 2016; Health and Social
Care Information Centre, 2015; Nutt and Rehm, 2014).
Alcohol causes a signiﬁcant amount of damage to
society and costs the National Health Service (NHS)
£billions each year (Balakrishnan et al., 2009; Boles
and Miotto, 2003; Bushman and Cooper, 1990).
Less harmful substances of abuse (van Amsterdam
et al., 2015) with potential therapeutic applica-
tions such as tetrahydrocannabinol and other can-
nabinoids (Grotenhermen and Muller-Vahl, 2012),
3,4-methylenedioxymethamphetamine (MDMA)
(Sessa and Nutt, 2015) and psilocybin (Johnson et al.,
2014) are not legally available at any form of retailer or
dispensary in the UK (Nutt, 2014). However, the UK
has some of the highest levels of recreational drug use
in Europe (EMCDDA, 2011).
Since the 1971 Misuse of Drugs Act, there has been
around a 13-fold increase in cannabis use with over
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10 million 16–59 year olds in England and Wales and
around 20% of young people reporting that they have
used cannabis (Weissenborn and Nutt, 2012). As pro-
hibitory approaches, particularly regarding cannabis,
have been ineﬀective (Gayle, 2015), and have done
little to limit the number of individuals consuming rec-
reational drugs (Hickman et al., 2007), the case for
treating recreational drug use as a health issue is
strong (Csete et al., 2016). An alternative regulatory
model utilising healthcare workers such as pharmacists,
general practitioners (GPs) and mental health workers
could perhaps more eﬀectively minimise overall societal
and health harms.
Prohibition of cannabis has had little positive impact
on the physical and mental health of users (Kuepper
et al., 2011; Moore et al., 2007) and in recent years
synthetic cannabinoids have become more widely used
which are signiﬁcantly more dangerous than naturally
occurring phytocannabinoids (Nia et al., 2016).
Legalisation of cannabis in some US states has not
led to a dramatic increase in the number of users
(Hasin et al., 2015) or traﬃc accidents (Balko, 2015).
The Colorado economy has beneﬁtted since legalising
cannabis for both therapeutic and recreational use with
legal cannabis activities generating an estimated $2.39
billion in state output and 18,005 new jobs in 2015
(Light et al., 2016).
MDMA has been used as an adjunct to psychother-
apy for decades and has been found, in clinical observa-
tion and case reports, to be eﬀective in empathy training
for couples experiencing interpersonal diﬃculties (Greer
and Tolbert, 1986; Metzner, 2014; Shulgin and Shulgin,
1991; Stolaroﬀ, 2004). MDMA is currently undergoing
clinical trials for post-traumatic stress disorder therapy,
in light of data strongly suggestive of therapeutic poten-
tial for the treatment of PTSD (Mithoefer et al., 2010,
2012), and anxiety in patients facing terminal illness
(Nichols, 2014). MDMA could become an available
therapeutic tool in the future and the NHS may need
to adapt to integrate MDMA-assisted psychotherapy
into the healthcare system.
The enhancement of interpersonal closeness and
sociability has been attributed to MDMA’s eﬀective-
ness as a therapeutic tool for psychotherapy
(Mithoefer et al., 2010) and its continual popularity
(Peters and Kok, 2009). MDMA continues to be a
prevalent party drug (Reynolds, 1998; United Nations
Oﬃce on Drugs and Crime, 2012) and there has
recently been a rise in the usage of MDMA and other
stimulants (Lader, 2015).
In contrast to alcohol (Abbey, 2002; Acierno et al.,
1997; Boles and Miotto, 2003; Nutt et al., 2010; Public
Health England, 2014; Taylor and Chermack, 1993)
and more harmful stimulants such as cocaine (Banks
et al., 2008), mephedrone (Jones et al., 2016) and novel
psychoactive substances (Westwell et al., 2013),
MDMA reliably enhances empathy and prosocial
behaviour (Bedi et al., 2010; Bershad et al., 2016;
Hysek et al., 2013; Kamilar-Britt and Bedi, 2015;
Wardle et al., 2014). Deaths from ecstasy are often due
to more harmful compounds such as PMA (Byard et al.,
1998). Poor quality and false MDMA is a predictable
outcome of an unregulated black market industry. In
other cases, users have simply taken far too much or
otherwise used MDMA irresponsibly (Kalant, 2001).
Psilocybe mushrooms have been used in healing
practices throughout history (Blinderman, 2016) and
prehistory (Guerra-Doce, 2015). Although psilocybin
is reportedly relatively safe (van Amsterdam et al.,
2010), can lead to meaningful positive experiences
(Carhart-Harris and Nutt, 2010) and is a potentially
life improving compound (Griﬃths et al., 2008), psilo-
cybe mushrooms are currently class A drugs with up to
seven years in prison for possession.
Psilocybin has been the subject of considerable
research for the treatment of psychological conditions
such as depression (Carhart-Harris et al., 2016), in pal-
liative care (Griﬃths et al., 2016; Grob et al., 2011;
Kelmendi et al., 2016; Nichols, 2014; Ross et al., 2016)
and for the treatment of alcohol and tobacco dependence
(Bogenschutz et al., 2015; Garcia-Romeu et al., 2014;
Johnson et al., 2014, 2017;Nichols, 2014). Recent studies
have heralded the ‘successful return of psychedelics to
psychiatry’ (Kleber, 2016) and new treatment alterna-
tives to selective-serotonin reuptake inhibitors, SSRIs,
are urgently needed for psychological conditions such
as anxiety and existential distress in patients with life-
threatening illness (Frazer and Benmansour, 2002;
Lieberman and Shalev, 2016; McCorvy et al., 2016;
Shelton and Hendricks, 2016; Spiegel, 2016).
The aims of the research were to assess how well the
public’s perception of the risks associated with the use
of ﬁve well-studied substances of abuse corresponds to
reported dangers posed by the substances. The research
also sought to determine which types of vendor are
most suitable for selling alcohol, tobacco, cannabis,
MDMA and psilocybin according to a general popula-
tion sample and to give an indication of whether or not
the general population might support the substances
being sold primarily in pharmacies for harm reduction
purposes. The primary outlets for drugs are pharma-
cies, regulated shops and the black market, and these
simple encompassing terms were used for the survey.
It was not hypothesised that pharmacies would be
perceived to be the most suitable primary vendors of
alcohol and tobacco, and these substances were
included to ensure the study was a fair test. Mental
health workers were included in the healthcare model
as the therapeutic uses of MDMA and psilocybin
require the presence of psychotherapists and
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recreational drug use has been partly attributed to psy-
chological and social factors (Hadaway et al., 1979).
A general population sample was used for this pre-
liminary exploratory survey as changes in the regulatory
environment of the substances discussed would be
enacted due to changes in policy. Government policy is
shaped by elected representatives and therefore the views
of the general population. The study was designed with
potential policy makers in mind so that an idea of the
perceptions and views of the public in the UK can be
determined and therefore help to guide policy.
Methods
This research obtained ethical approval from the
Cardiﬀ University School of Psychology ethics commit-
tee and was carried out with the informed consent of
the participants.
Participant recruitment
Participants were recruited from the Qualtrics research
panel, a volunteer panel that participate in online sur-
veys. The link provided basic information about the
study: ‘This study concerns the relative perceptions
and psychology of risk and risk management of speciﬁc
drugs’. The aim was to select a general population
sample of adults (see inclusion criteria) without requir-
ing prior use of recreational drugs, knowledge of drug
laws or background information about the topic.
Survey administration
The survey was designed to not be too intellectually
challenging as the sample used was a general popula-
tion sample. The scientiﬁc content was kept to a min-
imum to reduce the likelihood of problems with
compliance and understanding of the data and infor-
mation provided. Participants were required to com-
plete the survey in one sitting. The survey was
administered using Qualtrics, an online survey and
data-collection software tool.
Participants were initially asked about perceptions of
relative harm and were then presented information
regarding reported relative harm and potential thera-
peutic applications before proceeding to answer ques-
tions pertinent to harm reduction. The contents of the
data and information are viewable in the online
Supplementary material.
Inclusion criteria
All participants were required to: consent to participat-
ing in the study; be UK nationals; aged 18 years or
older.
Questions
The ﬁrst question relevant to this report was designed
to record participants’ perceptions of relative harm and
was answerable on a scale of 1–5. All following ques-
tions reported herein were answerable by a 1–10 scale.
For each of the questions, respondents were asked to
answer the question relative to alcohol, tobacco, can-
nabis, MDMA and magic mushrooms/psilocybin. The
wording of the questions was kept as consistent and
understandable as possible. Data from participants
were not included, for questions about the practicality
and relative support for being sold in pharmacies, if the
participant did not answer the question, selected ‘1’ for
all options or selected ‘don’t know’.
Demographics
Participants provided basic demographic information
regarding: age, education, gender and profession.
Participants were also invited to include: ‘other relevant
personal information’.
Results
Survey completion
All 105 participants consented to taking part in the
survey and completed it. Of these, six participants did
not meet the inclusion criteria for the practicality ques-
tion and two participants were not included for phar-
macy support questions.
Participant characteristics
The demographics of the 105 participants are as fol-
lows: 53 males and 52 females; 20 participants aged
18–24, 22 aged 25–34, 21 aged 35–44, 21 aged 45–54
and 21 aged 55þ; all UK nationals; 17 with GCSEs
(General Certiﬁcate of Secondary Education) or
equivalent, 23 with A-levels or equivalent, 5 with
vocational training (e.g. apprenticeship), 47 with a
bachelor’s degree, 9 with a master’s degree and 4 with
a PhD.
Perceived harm
Question: ‘Please give each of the ﬁve substances listed
a number between 1 and 5 where (1) is not at all harmful
to the consumer and to others and (5) is very harmful
based on your understanding and experience. Please
take addictive potential, typical regularity of consump-
tion and long-term eﬀects over an individual’s lifetime
into account’ (Table 1).
Participants initially perceived the relative harm as
follows: tobacco>MDMA> psilocybin> alcohol>
James et al. 3
cannabis (Table 1). An analysis of variance showed
that there was a highly signiﬁcant diﬀerence between
drugs (F 4,416¼ 28.9 p< 0.001). Planned comparisons
showed that tobacco was rated as more harmful than
the other drugs, and MDMA, psilocybin and alcohol
more harmful than cannabis. The data suggest that the
initial perceptions of the general population sample
used do not correlate with the relative harm reported
in the literature (Nutt et al., 2010). The initial percep-
tions of relative harm and therapeutic utility would
likely heavily inﬂuence the participants’ responses to
many of the following questions. Therefore, the data
in Table 1 justify the need to present the participants
with contemporary information regarding relative
harm and potential therapeutic applications. Relevant
information was presented to the participants following
recording data on perceived harm (see online
Supplementary material) before further questions
were asked.
Most suitable vendor
Question: ‘From the point of view of harm minimisation
to the individual consumer and to society as a whole
which type of vendor is most suited to being legally
permitted to sell the ﬁve substances discussed?’
(Tables 2 and 3).
The available options were:
. Pharmacist with available NHS support from GPs
and mental health workers;
. Shop that follows laws and regulations (e.g.
supermarket);
. Unregulated black market street/online vendor.
The data (Table 2) suggest that pharmacies with
available NHS support from GPs and mental health
workers are not the most suitable vendors of alcohol
or tobacco but are of cannabis, MDMA and
psilocybe mushrooms. The participants may have rea-
soned for the purposes of reducing the harm that rec-
reational use can cause and maximising the therapeutic
utility of the substances. An analysis of variance
showed that pharmacies were the preferred outlet
(F 2,208¼ 54.9 p< 0.001) and that ratings for cannabis
and MDMA were higher than psilocybe mushrooms
(F 4,416¼ 8.0 p< 0.001). The opinion that pharmacies
were the preferred outlet was stronger for MDMA than
the other drugs (drug outlet interaction: F 8,832¼
23.0 p< 0.001). The above results held up across
gender and age. The pharmacy eﬀect was signiﬁcantly
greater for those with University education.
Practicality of pharmacies as primary legal vendor
Question: ‘Making pharmacies the primary legal ven-
dors of the ﬁve substances discussed is practical and
realistic’ (Tables 4 and 5).
The data in Table 4 do not suggest that making
pharmacies the primary vendors of alcohol and tobacco
Table 2. Most suitable vendor data (N¼ 105)
Substance and vendor Mean SD Mode
Alcohol
Pharmacy 5.32 3.02 1
Shop 6.94 2.66 10
Black market 3.91 3.14 1
Tobacco
Pharmacy 5.54 3.00 1
Shop 6.42 2.88 10
Black market 3.74 3.05 1
Cannabis
Pharmacy 6.74 2.93 10
Shop 5.06 3.22 1
Black market 3.63 3.06 1
MDMA
Pharmacy 6.32 3.06 10
Shop 4.13 3.06 1
Black market 3.58 3.05 1
Psilocybin
Pharmacy 5.89 3.17 1þ 10
Shop 4.17 3.07 1
Black market 3.57 3.13 1
Table 1. Perceived harm scores (N¼ 105)
Substance Mean SD
Alcohol (e.g. beer/wine/vodka) 3.65 0.94
Tobacco (smoked) 4.45 0.82
Cannabis (herbal form
vaporised/smoked/ingested)
3.29 1.12
MDMA (high purity pharmaceutical quality) 4.17 0.91
Psilocybin (when consumed as mushrooms) 3.73 1.08
Table 3. Most suitable vendors of the five substances
Substance Most suitable vendor
Alcohol Shop
Tobacco Shop
Cannabis Pharmacy
MDMA Pharmacy
Psilocybin Pharmacy
4 Drug Science, Policy and Law 0(0)
is realistic. This result is especially clear when looking
at the mode scores. The lowest standard deviation
within the total sample and university-educated group
for the practicality of making pharmacies the primary
legal vendors of cannabis suggests the highest degree of
conﬁdence of all the ﬁve substances. Making pharma-
cies the primary legal vendors of cannabis, MDMA and
psilocybe mushrooms for the purposes of harm reduc-
tion and maximising the therapeutic utility of the sub-
stances is realistic according to the participants.
Alcohol and tobacco in pharmacies
Questions were asked to determine whether making
pharmacies the primary legal vendors of alcohol and
tobacco would be a positive change that the partici-
pants would support. However, as data in Tables 2
and 4 suggest that this is not realistic and that regulated
shops are the most suitable legal vendor, the data
obtained are not discussed in detail. Data from these
questions can be seen in Tables 9 and 10, Figure 7 and
in the online Supplementary material.
Cannabis in pharmacies
Question: ‘If cannabis were to be legalised for medicinal
and recreational use and sold in pharmacies with avail-
able NHS support from GPs and mental health work-
ers, as 1. A safer recreational drug alternative to
alcohol and tobacco 2. A source of therapeutic com-
pounds (such as THC, CBD and other cannabinoids)
and 3. So pharmacists can give advice and guidance on
safe usage practices, this would be a positive change
that you would support’ (Figures 1 and 2; Table 6).
Of the ﬁve substances discussed in this study, canna-
bis is the substance which received the highest level of
support to be sold in pharmacies as evidenced by the
highest support score of 7.02 from the total sample.
Fifty-seven percent of the total 45 non-university-
educated participants chose 6 or above for cannabis
being available in pharmacies as did 81% of the total
60 university-educated participants. Unlike with the
other substances, there was no signiﬁcant resistance to
Table 4. The practicality of pharmacies as primary vendors
Substance
Total score (N¼ 99) University-educated score (N¼ 57)
Mean (SD) Mode Mean (SD) Mode
Alcohol 4.92 (3.42) 1 5.12 (3.48) 1
Tobacco 5.15 (3.14) 1 5.61 (3.15) 1
Cannabis (therapeutic and recreational use) 6.90 (2.43) 5þ 10 7.54 (1.97) 9
MDMA (therapeutic and recreational use) 6.41 (2.90) 10 6.95 (2.71) 10
Psilocybin (therapeutic and recreational use) 6.01 (3.04) 10 6.63 (2.74) 10
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Figure 2. Relative support for cannabis to be legally available in
pharmacies. Number of participants who selected the specific
support score (1–10).
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Figure 1. Relative support for cannabis to be legally available in
pharmacies. Number of participants who selected ‘No’ (1–5) vs.
‘Yes’ (6–10).
Table 5. Likert-style results for practicality of pharmacies as
primary vendors
Substance Total score
Alcohol No
Tobacco Neither agree nor disagree
Cannabis Yes
MDMA Yes
Psilocybin Yes
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cannabis being available in pharmacies as evidenced by
the low number of 30 (out of 105) participants choosing
1–5. A majority of both the non-university-educated
and university-educated participants support the pro-
posed change in policy.
MDMA in pharmacies
Question: ‘If MDMA were to be legalised for thera-
peutic and recreational use and sold in pharmacies
with available NHS support from GPs and mental
health workers, as 1. A safer recreational drug alterna-
tive to alcohol and tobacco 2. A rational evidence-
based solution to the ongoing problem of unregulated
party drugs such as mephedrone 3. A potential thera-
peutic tool for psychotherapy and 4. So pharmacists
can give advice and guidance on safe usage practices,
this would be a positive change that you would support’
(Figures 3 and 4; Table 7).
The results for selling MDMA in pharmacies
demonstrate a greater level of support amongst the uni-
versity-educated participants than the non-university-
educated participants. Thirty-nine percent of the total
45 non-university-educated participants and 69% of the
total 60 university-educated participants chose 6 or
above for MDMA being available in pharmacies. If
the results (Table 7) are converted to a Likert-style
scale, the non-university-educated participants neither
agree nor disagree to MDMA being available in phar-
macies whereas the university-educated participants
agree.
Psilocybe mushrooms in pharmacies
Question: ‘If magic mushrooms were to be legalised for
therapeutic and recreational use and sold in pharmacies
with available NHS support from GPs and mental
health workers, as 1. A safer recreational drug alterna-
tive to alcohol and tobacco 2. A potential therapeutic
tool for psychotherapy and 3. So pharmacists can give
advice and guidance on safe usage practices, this would
be a positive change that you would support’ (Figures 5
and 6; Table 8).
The university-educated group mean support score
of 6.5 for psilocybin in pharmacies is equal to MDMA
(Tables 7 and 8). Forty-eight percent of the total 45
non-university-educated participants chose 6 or above
for psilocybin being available in pharmacies as did 69%
of the total 60 university-educated participants. If the
data are converted to a Likert-style scale, the non-
university-educated group neither agree nor disagree
whereas the university-educated group agree.
Further analysis
The data were searched for individuals whose profes-
sion or other personal details are relevant to the study.
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Figure 3. Relative support for MDMA to be legally available in
pharmacies. Number of participants who selected ‘No’ (1–5) vs.
‘Yes’ (6–10).
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Figure 4. Relative support for MDMA to be legally available in
pharmacies. Number of participants who selected the specific
support score (1–10).
Table 7. Relative support for MDMA to be legally available in
pharmacies
Education Mean (SD) Mode N
All participants 5.88 (2.97) 7þ 10 103
Non-university educated 5.00 (2.94) 5 44
University educated 6.54 (2.84) 7þ 10 59
Tabulated data compared across the total sample and educational level
(university educated and non-university educated).
Table 6. Relative support for cannabis to be legally available in
pharmacies
Education Mean (SD) Mode N
All participants 7.02 (2.52) 10 103
Non-university educated 6.30 (2.69) 5 44
University educated 7.56 (2.25) 10 59
Tabulated data compared across the total sample and educational level
(university educated and non-university educated).
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Police, drug users, healthcare workers, patients and
drug dealers are demographics that would arguably
be aﬀected by changes in the regulatory environment
of the substances discussed. The pharmacy support
scores for relevant individuals can be seen in Tables 9
and 10 and Figure 7.
Discussion
According to the participants making pharmacies the
primary legal vendors of alcohol and tobacco is not
realistic (Table 4), and regulated shops are more suit-
able legal vendors (Table 2). The existence of bars, oﬀ-
licences, supermarkets, restaurants and other stores
that sell alcohol as a drink and storage capacities of
1
2
3
4
5
6
7
8
9
10
D
is
a
gr
e
e
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ag
re
e
Pharmacies As Legal Vendors 
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Figure 7. Support scores for pharmacies as legal vendors of the
five substances. The mode score for MDMA is represented as the
average of the two mode scores.
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Figure 5. Relative support for psilocybin to be legally available
in pharmacies. Number of participants who selected ‘No’ (1–5)
vs. ‘Yes’ (6–10).
Table 9. Medical practitioner support scores for pharmacies as
legal vendors
Participant Alcohol Tobacco Cannabis MDMA Psilocybin
Carer
(rehabilitation)
3 8 10 10 10
Nurse (a) 1 9 10 3 6
Nurse (b) 1 1 10 7 8
Staff nurse 6 5 10 10 5
Counsellor 6 8 10 10 9
Physiotherapist 6 6 8 9 6
Mean 3.8 6.2 9.7 8.2 7.3
0
2
4
6
8
10
12
14
16
18
20
1 2 3 4 5 6 7 8 9 10
N
um
be
r o
f P
ar
tic
ip
an
ts
Support Score
Psilocybe Mushrooms in Pharmacies
Figure 6. Relative support for psilocybin to be legally available
in pharmacies. Number of participants who selected the specific
support score (1–10).
Table 10. Other relevant participant support scores for
pharmacies as legal vendors
Participant Alcohol Tobacco Cannabis MDMA Psilocybin
Drug user 6 7 8 7 7
‘Dealer’ 10 10 10 8 6
MS sufferer 2 1 8 9 2
Police officer 7 3 8 5 7
Healthcare
(manager)
10 10 7 8 8
Table 8. Relative support for psilocybin to be legally available in
pharmacies
Education Mean (SD) Mode N
All participants 5.87 (2.87) 8 103
Non-university educated 5.07 (3.14) 1 44
University educated 6.47 (2.51) 8 59
Tabulated data compared across the total sample and educational level
(university educated and non-university educated).
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existing pharmacies may have inﬂuenced the partici-
pants. Tobacco’s highly addictive nature means that
consumers need to be able to access it during most of
the 24 hours in a day (Benowitz, 2010). There may have
been a perception that not all smokers can easily obtain
their highly addictive drug in pharmacies due to geo-
graphical availability and opening times. Additionally,
there may have been an ideology-driven perception
that, as tobacco and alcohol have no accepted or poten-
tial therapeutic applications, they should not be sold in
pharmacies.
The data from the general population sample used
suggest that selling the currently illicit substances in
pharmacies is realistic and that pharmacies are the
most suitable legal vendor. Amsterdam style coﬀee
shops, implied by the regulated shop option, and
other forms of shop were not the favoured choice of
the participants. This may be due to the participants
perceiving that pharmacists are better qualiﬁed to dis-
pense cannabis, MDMA and psilocybin than people
with a non-medical background working in a shop.
In some countries, such as in some states in the
United States, people can access medical marijuana.
Applying a similar model to the UK would likely
mean that patients could obtain medicinal cannabis in
pharmacies with a prescription. However, prescription
access only cannabis would not mitigate the existence
of the black market for non-medical use nor would it
help users of cannabis who, without a legal medical
regulatory framework (Lamb et al., 2016), may have
an increased likelihood of developing psychological,
interpersonal or professional problems due to their rec-
reational use of cannabis (Nutt et al., 2010).
Cannabis is used to treat a broad range of diﬀerent
medical and psychiatric conditions including carcin-
oma, arthritis, glaucoma, stress, anxiety, depression,
anger, insomnia, chronic pain, epilepsy and neurode-
generative diseases (Amar, 2006; Compston and
Coles, 2002, 2008; Grotenhermen and Muller-Vahl,
2012; Hirst et al., 1998; Kumar et al., 2001;
Reinarman et al., 2011; Ware et al., 2004). It is there-
fore not without precedent that the medical practi-
tioners (Table 9) and the multiple sclerosis suﬀerer
located in the sample (Table 10) were supportive of
cannabis being legally available in pharmacies.
Participants were also perhaps pragmatic towards the
need for cannabis to be regulated as prohibition of can-
nabis has been particularly ineﬀective (Werb et al.,
2013).
Making pharmacies the primary legal vendors of
cannabis for therapeutic and recreational use is realistic
according to the participants (Table 4). Consequently, a
screening or a consultation between potential cannabis
users and GPs is perhaps achievable. Due to cannabis’
relatively high safety proﬁle (Taylor et al., 2012;
Zajicek et al., 2005), it is probable that only a minority
of the general population would not receive consent to
use cannabis sold in a healthcare setting after a consult-
ation with their GP.
The precise roles of GPs, pharmacists and mental
health workers in such a modiﬁed regulatory environ-
ment are undetermined. Two access routes to cannabis
could possibly be available: (1) Cannabis with a pre-
scription and (2) Harm minimisation intervention in
which pharmacists maximise the therapeutic utility of
cannabis.
Pharmacies can be strictly regulated, and pharma-
cists can adhere to a strict code of ethical conduct
(Resnik et al., 2000). If dispensing for non-medical
use, pharmacists could recommend strains with lower
overall concentrations of THC and higher proportion
CBD than modern black market cannabis (Russo,
2011; Schubart et al., 2011). Pharmacists could also
provide harm reduction advice such as not to smoke
cannabis mixed with tobacco (Aldington et al., 2007;
Lachenmeier and Rehm, 2015; Ribeiro and Ind, 2016;
Tashkin, 2012) and that using a vaporiser is likely less
harmful than smoking (Cozzi, 1993; Gieringer et al.,
2004). Alternatively, pharmacists could recommend
ingestion of cannabis which mitigates the potential dan-
gers of smoking; however, they would also need to
convey the unique risks of ingestion, such as stronger
potential eﬀects, as drug strength is less easily titrated
in real-time compared to other methods of
administration.
Research has suggested that chronic daily use of can-
nabis is associated with increased likelihood of develop-
ing psychosis (Bran˜as et al., 2016) and by being the
primary legal vendors of cannabis, pharmacists would
be in a position to stress that infrequent use of cannabis
presents signiﬁcantly less risk than heavy use. High-risk
individuals such as people with a family history of
mental illness may be at a lower risk of developing
cannabis-related mental health problems if cannabis is
primarily available in a healthcare setting in which
trained medical practitioners can oﬀer practical advice
and guidance.
Although MDMA is a comparatively safe stimulant,
referred to both as an entactogen and empathogen,
with the potential to give users deeply meaningful and
positive experiences (Baggott et al., 2016; Bedi et al.,
2014; Bershad et al., 2016; Kirkpatrick et al., 2012;
Schmid et al., 2014, 2015; Wardle and de Wit, 2012),
it can cause considerable harm and death to users. As
the participants concluded that making pharmacies the
primary legal vendors of MDMA is practical and real-
istic, a mandatory GP consultation and screening of
potential MDMA users is feasible. Doctors and
pharmacists working in combination could act to edu-
cate MDMA users on safe usage practices and minimise
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the risk posed to individuals (Becker and Hu, 2008;
Global Drugs Survey, 2016).
MDMA cannot be used with the same frequency as
alcohol, and chronic daily use can lead to severe mental
health problems (McGuire et al., 1994). However,
MDMA has lower addiction potential than other
stimulants such as cocaine or methamphetamine, and
regular chronic use is rare (Solowij et al., 1992). If
MDMA were only legally available in pharmacies,
then pharmacists would be able to stress that infrequent
moderate usage of MDMA poses signiﬁcantly less risk
(Laursen et al., 2016).
Typically for a drug to reach market, it needs to be
approved by theFDA in theUS and theEMA inEurope,
but this route only applies to medicines. Any change in
substance abuse management is determined by policy.
The participants in this study concluded that in order
to reduce recreational drug harms, MDMA could be
available in a healthcare context. The data in Figures 3
and 4 and Table 7 are suggestive that the general popu-
lation on the whole would not oppose MDMA being
available in pharmacies when presented with informa-
tion regarding therapeutic uses and relative harm. Six
healthcare practitioners located within the sample had
ameanMDMAsupport score of 8.2 (Table 9) suggesting
that those healthcare workers were supportive of
MDMA being available in a healthcare setting.
While empirically psilocybe mushrooms are one of
the safest recreational drugs known, due to extremely
rare mortality (Ghodse et al., 2013; Lader, 2015),
uncontrolled recreational use of psilocybe mushrooms
would pose a considerable risk to the mental health of
vulnerable individuals (Barrett et al., 2016).
Unquestioning acceptance of the therapeutic value of
hallucinogens such as LSD has historically proven to be
dangerous, and the medical profession has an obliga-
tion to ensure that the questionable ‘Turn on, tune in,
drop out’ message of Timothy Leary in the late 1960s is
not repeated (Goodwin, 2016). As with treating
patients for psycho-existential distress (Blinderman,
2016), medical practitioners would have an obligation
to reduce the likelihood of adverse reactions to
psilocybin.
Making pharmacies the primary legal vendors
of psilocybe mushrooms is practical and realistic
(Table 4). GPs would therefore be able to consult
with and screen potential psilocybe mushroom users.
Screening of potential users of psilocybin is essential
as the hallucinogen can induce acute and, albeit
rarely, persistent adverse psychological reactions
(Johnson et al., 2008). However, many challenging
experiences or ‘bad trips’ upon later reﬂection are per-
ceived to have been beneﬁcial (Carbonaro et al., 2016).
As psilocybe mushrooms cause little damage to soci-
etal and personal wellbeing and may have a net positive
eﬀect (Carhart-Harris and Nutt, 2010, 2013) any psi-
locybe mushroom service need not necessarily be
viewed as being for the purposes of reducing the
harms caused by psilocybe mushrooms. Any non-
prescription service provided by pharmacists and
therapists should aim to maximise the therapeutic util-
ity of psilocybin. Any non-prescription psilocybin
intervention could therefore perhaps be termed a posi-
tive psychology intervention (Shelton and Hendricks,
2016). A positive psychology intervention with
approval from a GP, pharmacist and therapist could
be an uplifting alternative to other non-essential or
non-therapeutic uses of psychoactive substances
(Hendricks et al., 2015).
A psilocybin study for severely depressed and anx-
ious patients with life-threatening cancer was con-
ducted in ‘an aesthetic living-room-like environment
with two monitors present’ (Griﬃths et al., 2016).
A mode of administration protocol would need to be
developed (Breckenridge and Grobbee, 2016) as cur-
rently there is no precedent in the healthcare delivery
model for the types of protocols that are followed in
psilocybin-assisted psychotherapy. Specially trained
healthcare professionals are required and they need to
be present throughout the psilocybin experience
(Johnson et al., 2008). Pharmacies with specialised
rooms and on-site psychotherapists may, therefore, be
a potential location for psilocybin interventions.
Considering psilocybin’s putative role as a meaning
response enhancer would likely be an essential integral
part of any psilocybin intervention. Preparation, music,
plants, pictures and the attitudes of individuals
involved in the set and setting of the experience are
all key extra-pharmacological components. Improved
therapeutic outcomes of psilocybin experiences are
probable if medical professionals with a positive atti-
tude have administered the experience as opposed to a
black market distributor or staﬀ in a regulated shop
(Carhart-Harris et al., 2016; Hartogsohn, 2016).
Facilitating mystical experiences would likely also be
an integral part in any psilocybin intervention as sub-
jects’ mystical experiences are reported as being highly
correlated with therapeutic outcomes and beneﬁcial
long-term eﬀects (Garcia-Romeu et al., 2014; Griﬃths
et al., 2016; Kelmendi et al., 2016; MacLean et al.,
2011; Ross et al., 2016; Summergrad, 2016).
To conclude, the study described herein used all UK
participants, UK-speciﬁc data and information
and asked questions directly relating to the UK
National Health Service. The data collected are there-
fore not applicable to other countries with diﬀerent
population demographics, healthcare systems and
recreational drug problems. Such drawbacks limit the
generalisability of the results of this study to other
countries.
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Although the sample size was relatively small (105),
the study utilised an unbiased recruitment strategy.
Other studies with recruitment strategies that include
advertising on websites frequented by recreational
drug users limit their objective reliability, whereas the
participants in this study were not recruited due to any
pre-existing interest in recreational drugs. Further
research using a larger specialist healthcare sample
would be useful in determining whether a signiﬁcant
diﬀerence between the general population and health-
care practitioners does exist or whether the data
obtained from the six healthcare workers in this
sample (Table 9) are simply attributable to the cluster-
ing illusion.
Overall, the data suggest that changes in the legal
status or the implementation of harm reduction strate-
gies, with regard to cannabis, MDMA and psilocybin
being sold in pharmacies, would likely not be associated
with signiﬁcant resistance from the public in the UK.
However, this ﬁnding should be interpreted with great
care and caution as public support for harm reduc-
tion strategies does not necessarily suggest that harm
reduction strategies are warranted. Whether such
changes should actually be made and the public
health impacts of such changes cannot be determined
from the current study. Cannabis, MDMA and psilo-
cybin remain controlled drugs in many countries,
including the UK, severely restricting possession and
supply. Changes to the status of these substances, so
that they can be made available and managed through
licensed outlets such as pharmacies, will require legis-
lative change promoted by clear evidence of therapeutic
beneﬁt.
In summary, the data suggest that the general popu-
lation are supportive of currently criminalised com-
pounds with potential therapeutic applications being
utilised in treatments. Schedule changes of phytocanna-
binoids, MDMA and psilocybin from schedule 1 are
needed to achieve this. The results of this study are
supportive of the hypothesis that the general popula-
tion in the United Kingdom are comfortable treating
recreational drug use as health issue with GPs, mental
health workers and pharmacists playing roles.
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